These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 15905854)

  • 21. Antisense strategy in hematological malignancies.
    Warzocha K
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I
    Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method.
    Yildiz D; Oztas H; Hilal Ates B
    Med Hypotheses; 2005; 64(2):328-32. PubMed ID: 15607566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ribosomal protein P2: a potential molecular target for antisense therapy of human malignancies.
    Gardner-Thorpe J; Ito H; Ashley SW; Whang EE
    Anticancer Res; 2003; 23(6C):4549-60. PubMed ID: 14981896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Making sense of antisense.
    Vidal L; Blagden S; Attard G; de Bono J
    Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of antisense oligonucleotides in the treatment of bladder cancer.
    Duggan BJ; Gray S; Johnston SR; Williamson K; Miyaki H; Gleave M
    Urol Res; 2002 Jul; 30(3):137-47. PubMed ID: 12111175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.
    Xu M; Lu X; Kallinteris NL; Wang Y; Wu S; von Hofe E; Gulfo JV; Humphreys RE; Hillman GG
    Curr Opin Mol Ther; 2004 Apr; 6(2):160-5. PubMed ID: 15195928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A role for intracellular immunization in chemosensitization of tumor cells?
    Pich A; Rancourt C
    Gene Ther; 1999 Jul; 6(7):1202-9. PubMed ID: 10455428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
    Kim R; Emi M; Matsuura K; Tanabe K
    Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The roles of microRNA in cancer and apoptosis.
    Lynam-Lennon N; Maher SG; Reynolds JV
    Biol Rev Camb Philos Soc; 2009 Feb; 84(1):55-71. PubMed ID: 19046400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisense oligonucleotides.
    Herdewijn P
    Verh K Acad Geneeskd Belg; 1996; 58(4):359-81. PubMed ID: 8956554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Progress in molecular biology of leukemias--clinical implications].
    Skórski T
    Acta Haematol Pol; 1995; 26(2 Suppl 1):14-8. PubMed ID: 7653230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy.
    Tidd DM
    Anticancer Res; 1990; 10(5A):1169-82. PubMed ID: 2241097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Gene therapy in cancer].
    Hovig E; Myklebost O; Aamdal S; Smeland EB
    Tidsskr Nor Laegeforen; 2001 Feb; 121(4):482-8. PubMed ID: 11255868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of antisense therapy: combination with anticancer treatments.
    Biroccio A; Leonetti C; Zupi G
    Oncogene; 2003 Sep; 22(42):6579-88. PubMed ID: 14528283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcl-2 family members as molecular targets in cancer therapy.
    Marzo I; Naval J
    Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.
    Sieghart W; Losert D; Strommer S; Cejka D; Schmid K; Rasoul-Rockenschaub S; Bodingbauer M; Crevenna R; Monia BP; Peck-Radosavljevic M; Wacheck V
    J Hepatol; 2006 Jan; 44(1):151-7. PubMed ID: 16289418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides.
    Ma X; Wang S; Zhou J; Xing H; Xu G; Wang B; Chen G; Lu YP; Ma D
    Oncol Rep; 2005 Jul; 14(1):275-9. PubMed ID: 15944801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications.
    Calabretta B
    Cancer Res; 1991 Sep; 51(17):4505-10. PubMed ID: 1873794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.